-----BEGIN PRIVACY-ENHANCED MESSAGE-----
Proc-Type: 2001,MIC-CLEAR
Originator-Name: webmaster@www.sec.gov
Originator-Key-Asymmetric:
 MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen
 TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB
MIC-Info: RSA-MD5,RSA,
 FoAt71QVylRzjWdQv6jmRH+jlIczvKjxS522KePdDiZ6USMNSmnii+mJqCdQ4w8K
 5orlzVYXYBpBxIP18yGJmQ==

<SEC-DOCUMENT>0000950123-10-005758.txt : 20100127
<SEC-HEADER>0000950123-10-005758.hdr.sgml : 20100127
<ACCEPTANCE-DATETIME>20100127172940
ACCESSION NUMBER:		0000950123-10-005758
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		4
CONFORMED PERIOD OF REPORT:	20100127
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20100127
DATE AS OF CHANGE:		20100127

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Cyclacel Pharmaceuticals, Inc.
		CENTRAL INDEX KEY:			0001130166
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				911766850
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-50626
		FILM NUMBER:		10551440

	BUSINESS ADDRESS:	
		STREET 1:		200 CONNELL DRIVE
		STREET 2:		SUITE 1500
		CITY:			BERKELEY HEIGHTS
		STATE:			NJ
		ZIP:			07922
		BUSINESS PHONE:		908-517-7330

	MAIL ADDRESS:	
		STREET 1:		200 CONNELL DRIVE
		STREET 2:		SUITE 1500
		CITY:			BERKELEY HEIGHTS
		STATE:			NJ
		ZIP:			07922

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	XCYTE THERAPIES INC
		DATE OF NAME CHANGE:	20001218
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>c95090e8vk.htm
<DESCRIPTION>8-K
<TEXT>
<HTML>
<HEAD>
<TITLE>8-K</TITLE>
</HEAD>
<BODY bgcolor="#FFFFFF">
<!-- PAGEBREAK -->

<DIV style="font-family: 'Times New Roman',Times,serif; margin-left: .25in; width: 7.20in">



<DIV style="font-size: 10pt">
<DIV style="width: 100%; border-bottom: 2pt solid black; font-size: 1pt">&nbsp;</DIV>
<DIV style="width: 100%; border-bottom: 1pt solid black; font-size: 1pt">&nbsp;</DIV>


<P align="center" style="font-size: 14pt"><B>UNITED STATES<BR>
SECURITIES AND EXCHANGE COMMISSION<BR>
<FONT style="font-size: 12pt">Washington, D.C. 20549
</FONT></B>

<P align="center" style="font-size: 18pt"><B>FORM 8-K</B>

<P align="center" style="font-size: 12pt"><B>CURRENT REPORT<BR>
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934</B>

<P align="center" style="font-size: 10pt"><B>Date of Report (Date of earliest event reported): January 27,  2010</B>

<P align="center">

<P align="center" style="font-size: 24pt"><B>CYCLACEL PHARMACEUTICALS, INC.<BR></B>
<FONT style="font-size: 10pt">(Exact name of registrant as specified in its charter)
</FONT>

<TABLE border="0" width="100%" cellspacing="0" cellpadding="0" style="font-size: 10pt; text-align: center">
<TR>
    <TD width="32%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="33%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="32%">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD style="border-bottom: 1px solid #000000"><B>Delaware</B></TD>
    <TD>&nbsp;</TD>
    <TD style="border-bottom: 1px solid #000000"><B>0-50626</B></TD>
    <TD>&nbsp;</TD>
    <TD style="border-bottom: 1px solid #000000"><B>91-1707622</B></TD>
</TR>
<TR valign="top">
    <TD>(State or other Jurisdiction of Incorporation)</TD>
    <TD>&nbsp;</TD>
    <TD>(Commission File Number)</TD>
    <TD>&nbsp;</TD>
    <TD>(IRS Employer Identification No.)</TD>
</TR>
</TABLE>

<TABLE border="0" width="100%" cellspacing="0" cellpadding="0" style="font-size: 10pt; text-align: center">
<TR>
    <TD width="49%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="49%">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD style="border-bottom: 1px solid #000000"><B>200 Connell Drive, Suite 1500<BR>Berkeley Heights, NJ<BR></B></TD>
    <TD>&nbsp;</TD>
    <TD style="border-bottom: 1px solid #000000"><B>07922</B></TD>
</TR>
<TR valign="top">
    <TD>(Address of Principal Executive Offices)</TD>
    <TD>&nbsp;</TD>
    <TD>(Zip Code)</TD>
</TR>
</TABLE>

<P align="center" style="font-size: 10pt">Registrant&#146;s telephone number, including area code: <B>(908) 517-7330</B>


<TABLE border="0" width="30%" cellspacing="0" cellpadding="0" style="font-size: 10pt; text-align: center">
<TR>
    <TD width="100%">&nbsp;</TD>
</TR>
<TR>
    <TD nowrap style="border-bottom: 1px solid #000000"><B>&nbsp;</B></TD>
</TR>
<TR>
    <TD nowrap>(Former name or former address if changed since last report.)</TD>
</TR>
</TABLE>

<P align="left" style="font-size: 10pt">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions:

<P align="left" style="font-size: 10pt">
<FONT face="Wingdings">&#111;</FONT> Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)<BR><BR>
<FONT face="Wingdings">&#111;</FONT> Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)<BR><BR>
<FONT face="Wingdings">&#111;</FONT> Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))<BR><BR>
<FONT face="Wingdings">&#111;</FONT> Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))<BR>


<P>
<DIV style="width: 100%; border-bottom: 1pt solid black; margin-top: 10pt; font-size: 1pt">&nbsp;</DIV>
<DIV style="width: 100%; border-bottom: 2pt solid black; font-size: 1pt">&nbsp;</DIV>

</DIV>

<P align="center" style="font-size: 10pt">&nbsp;

<P align="center" style="font-size: 10pt; display: none">1
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif; margin-left: .25in; width: 7.20in">

<P align="justify" style="font-size: 10pt"><B>Item&nbsp;8.01 Other Events</B>


<P align="justify" style="font-size: 10pt; text-indent: 4%">On January&nbsp;27, 2010, Cyclacel Pharmaceuticals, Inc. (the &#147;<B>Company</B>&#148;) issued a press release announcing that NASDAQ
has notified the Company that it has regained compliance with the minimum $50&nbsp;million market value of listed securities
requirement and that it currently complies with all other applicable standards for continued listing on The NASDAQ
Global Market. Accordingly, the Company&#146;s shares of common and
preferred stock will continue to trade on The NASDAQ Global Market and the previously
disclosed delisting proceeding is now closed. Attached as Exhibit&nbsp;99.1 is a copy of the press release.


<P>
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left"><B>Item&nbsp;9.01</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD><DIV style="text-align: justify"><B>Financial Statements and Exhibits</B></DIV></TD>
</TR>

</TABLE>


<P>
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">(d)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><DIV style="text-align: justify">The following exhibit is furnished with this Report:</DIV></TD>
</TR>

</TABLE>

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="11%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="84%">&nbsp;</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom">
    <TD nowrap align="left" style="border-bottom: 1px solid #000000">Exhibit No</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" style="border-bottom: 1px solid #000000">Description</TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">99.1
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Press Release dated January&nbsp;27, 2010</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>

<P align="center" style="font-size: 10pt">&nbsp;

<P align="center" style="font-size: 10pt; display: none">2
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif; margin-left: .25in; width: 7.20in">



<P align="center" style="font-size: 10pt"><B>SIGNATURES</B>



<P align="justify" style="font-size: 10pt; text-indent: 4%">Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to
be signed on its behalf by the undersigned thereunto duly authorized.


<P align="justify" style="font-size: 10pt; margin-left: 46%; font-size: 10pt"><B>CYCLACEL PHARMACEUTICALS, INC.</B>


<P align="justify" style="font-size: 10pt; margin-left: 46%; font-size: 10pt">By: <U>/s/ Paul McBarron&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U><BR>
Name: Paul McBarron<BR>
Title: Executive Vice President&#151;Finance,<BR>
Chief Financial Officer and Chief Operating Officer<BR>


<P align="justify" style="font-size: 10pt">Date: January&nbsp;27, 2010


<P align="center" style="font-size: 10pt">&nbsp;

<P align="center" style="font-size: 10pt; display: none">3




</DIV>
</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>c95090exv99w1.htm
<DESCRIPTION>EX-99.1
<TEXT>
<HTML>
<HEAD>
<TITLE>EX-99.1</TITLE>
</HEAD>
<BODY bgcolor="#FFFFFF">
<!-- PAGEBREAK -->
<DIV style="font-family: Helvetica,Arial,sans-serif; margin-left: .25in; width: 7.20in">

<DIV align="right" style="font-size: 10pt; margin-top: 10pt"><B>Exhibit&nbsp;99.1</B>
</DIV>

<P><DIV style="position: relative; float: left; width: 48%">

<DIV align="left" style="font-size: 10pt; margin-top: 10pt"><IMG src="c95090p9509001.jpg" alt="(LOGO)">

</DIV>
</DIV>
<DIV style="position: relative; float: right; width: 48%">
<DIV align="right" style="font-size: 10pt; margin-top: 10pt"> &nbsp;
</DIV>

<DIV align="right" style="font-size: 10pt; margin-top: 10pt">Cyclacel Pharmaceuticals, Inc.
</DIV>

</DIV>
<BR clear="all"><BR>

<DIV align="center" style="font-size: 10pt; margin-top: 10pt"><IMG src="c95090p9509002.jpg" alt="(PRESS RELEASE)">
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 10pt"><B>CYCLACEL REGAINS NASDAQ COMPLIANCE</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt"><B>Berkeley Heights, NJ, January&nbsp;27, 2010 </B>&#151; Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ:
CYCCP; &#147;Cyclacel&#148; or the &#147;Company&#148;) today announced that NASDAQ notified the Company that it has
regained compliance with the minimum $50&nbsp;million market value of listed securities requirement, and
further, that it currently complies with all other applicable standards for continued listing on
The NASDAQ Global Market.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt">As required under NASDAQ&#146;s Listing Rules, to regain compliance, the Company was required to
evidence a market value of listed securities of $50&nbsp;million or more for at least ten consecutive
days. On January&nbsp;21, 2010, the market value of the Company&#146;s listed securities was approximately
$69.7&nbsp;million, the tenth consecutive day it had exceeded the $50&nbsp;million threshold. Accordingly,
the Company will continue to trade on The NASDAQ Global Market and the previously disclosed
delisting proceeding is now closed.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt"><B>About Cyclacel Pharmaceuticals, Inc.</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt">Cyclacel is a biopharmaceutical company dedicated to the discovery, development and
commercialization of novel, mechanism-targeted drugs to treat human cancers and other serious
disorders. Three orally-available Cyclacel drugs are in clinical development. Sapacitabine
(CYC682), a cell cycle modulating nucleoside analog, is in Phase 2 studies for the treatment of
acute myeloid leukemia in the elderly, myelodysplastic syndromes and lung cancer. The Company
plans to submit a Special Protocol Assessment (SPA)&nbsp;request for a pivotal study with sapacitabine
during the first quarter of 2010. Seliciclib (CYC202 or R-roscovitine), a CDK (cyclin dependent
kinase) inhibitor, is in Phase 2 studies for the treatment of lung cancer and nasopharyngeal cancer
and in a Phase 1 trial in combination with sapacitabine. CYC116, an Aurora kinase and VEGFR2
inhibitor, is in a Phase 1 trial in patients with solid tumors. Cyclacel&#146;s ALIGN Pharmaceuticals
subsidiary markets directly in the U.S. Xclair<SUP style="font-size: 85%; vertical-align: text-top">&#174;</SUP> Cream for radiation dermatitis, Numoisyn<SUP style="font-size: 85%; vertical-align: text-top">&#174;</SUP> Liquid
and Numoisyn<SUP style="font-size: 85%; vertical-align: text-top">&#174;</SUP> Lozenges for xerostomia. Cyclacel&#146;s strategy is to build a diversified
biopharmaceutical business focused in hematology and oncology based on a portfolio of commercial
products and a development pipeline of novel drug candidates. Please visit
<U>www.cyclacel.com</U> for additional information.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt"><B>Risk factors</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt">This news release contains certain forward-looking statements that involve risks and uncertainties
that could cause actual results to be materially different from historical results or from any
future results expressed or implied by such forward-looking statements. Such forward-looking
statements include statements regarding, among other things, the efficacy, safety, and intended
utilization of Cyclacel&#146;s product candidates, the conduct and results of future clinical trials,
plans regarding regulatory filings, future research and clinical trials and plans regarding
partnering activities. Factors that may cause actual results to differ materially include the risk
that product candidates that appeared promising in early research and clinical trials do not
demonstrate safety and/or efficacy in larger-scale or later clinical trials, the risk that Cyclacel
will not obtain approval to market its products, the risks associated with reliance on outside
financing to meet capital requirements, and the risks associated with reliance on collaborative
partners for further clinical trials, development and commercialization of product candidates. You
are urged to consider statements that include the words &#147;may,&#148; &#147;will,&#148; &#147;would,&#148; &#147;could,&#148; &#147;should,&#148;
&#147;believes,&#148; &#147;estimates,&#148; &#147;projects,&#148; &#147;potential,&#148; &#147;expects,&#148; &#147;plans,&#148; &#147;anticipates,&#148; &#147;intends,&#148;
&#147;continues,&#148; &#147;forecast,&#148; &#147;designed,&#148; &#147;goal,&#148; or the negative of those words or other comparable
words to be uncertain and forward-looking. These factors and others are more fully discussed under
&#147;Risk Factors&#148; in the Annual Report on Form 10-K for the year ended December&nbsp;31, 2008, as
supplemented by the interim quarterly reports, filed with the SEC.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt"><B>Contacts for Cyclacel Pharmaceuticals, Inc.</B>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt">Investors/Media:<BR>
Corey Sohmer, (908)&nbsp;517-7330<BR>
<U>csohmer@cyclacel.com</U>

</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt"><SUP style="font-size: 85%; vertical-align: text-top">&#169;</SUP> Copyright 2010 Cyclacel Pharmaceuticals, Inc. All Rights Reserved. The Cyclacel logo and
Cyclacel<SUP style="font-size: 85%; vertical-align: text-top">&#174;</SUP> are trademarks of Cyclacel Pharmaceuticals, Inc. Numoisyn<SUP style="font-size: 85%; vertical-align: text-top">&#174;</SUP> and Xclair<SUP style="font-size: 85%; vertical-align: text-top">&#174;</SUP> are trademarks
of Sinclair Pharma plc.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt">SOURCE: Cyclacel Pharmaceuticals, Inc.
</DIV>

<DIV align="left" style="font-size: 9pt; margin-top: 10pt"><FONT face="Wingdings">&#254;</FONT> 200 Connell Drive, Suite&nbsp;1500, Berkeley Heights, NJ 07922 USA T: &#043;1 (908)&nbsp;517 7330 F: &#043;1 (866)&nbsp;271 3466<BR>
<FONT face="Wingdings">&#111;</FONT> Dundee Technopole, James Lindsay Place, Dundee, DD1 5JJ, UK Tel &#043;44 1382 206 062 Fax &#043;44 1382 206 067
</DIV>
<DIV align="center" style="font-size: 10pt"><U>www.cyclacel.com</U> &#151; <U>info@cyclacel.com</U></DIV>




<P align="center" style="font-size: 10pt">&nbsp;

<P align="center" style="font-size: 10pt"><!-- Folio --><!-- /Folio -->
</DIV>




</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>c95090p9509001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 c95090p9509001.jpg
M_]C_X``02D9)1@`!``$`8`!@``#__@`?3$5!1"!496-H;F]L;V=I97,@26YC
M+B!6,2XP,0#_VP"$``("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("
M`@("`@,#`@(#`@("`P0#`P,#!`0$`@,$!`0$!`,$!`,!`@("`@("`@("`@,"
M`@(#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#
M`P,#`P,#`__$`:(```$%`0$!`0$!```````````!`@,$!08'"`D*"P$``P$!
M`0$!`0$!`0````````$"`P0%!@<("0H+$``"`0,#`@0#!04$!````7T!`@,`
M!!$%$B$Q008346$'(G$4,H&1H0@C0K'!%5+1\"0S8G*""0H6%Q@9&B4F)R@I
M*C0U-C<X.3I#1$5&1TA)2E-455976%E:8V1E9F=H:6IS='5V=WAY>H.$A8:'
MB(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4U=;7
MV-G:X>+CY.7FY^CIZO'R\_3U]O?X^?H1``(!`@0$`P0'!00$``$"=P`!`@,1
M!`4A,08205$'87$3(C*!"!1"D:&QP0DC,U+P%6)RT0H6)#3A)?$7&!D:)B<H
M*2HU-C<X.3I#1$5&1TA)2E-455976%E:8V1E9F=H:6IS='5V=WAY>H*#A(6&
MAXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&Q\C)RM+3U-76
MU]C9VN+CY.7FY^CIZO+S]/7V]_CY^O_``!$(`%@`U`,!$0`"$0$#$0'_V@`,
M`P$``A$#$0`_`/W\H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`
M*`"@`H`*`"@`H`*`"@`H`*`/,OB;\7?`_P`)-)&I^+M56">=7.F:+9JMSK6K
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MF_T3XFZY#<IYZR>(M0O[.TE4@Q!EAUN^MXE.W(VB-3C/&#7MK.^`<C?LZ&*R
MK!RI/EMAJ=.<XO>SE0ISEOK>[5^I\X^'/$WB%>TKX+.<;"HN=/%U:M.#7PZ+
M$U*<-M+))VZ:E&?]GOX_^&Y$O(?`'BFVGC;]W<:!=6MW=1,,.&1]$U&26,=/
MF&.1ZBMH<:\&8V+I2SG"2@UK'$0G"#Z:JO3C%^G8PGX>\?Y;*-6&08VG4B])
MX6<*DXO?1X:K*:]5I?S&Z)\</CO\,M02S;Q5XJM);?[V@^-8;O48&0EG939Z
M_&;B)6+D[X)(FY!#8`IXKA+@_/:+JQR["3C/;$8&4*4D]K\^':@[6M:<9+?2
MXL%QQQYPSB%1EFF.I2I[X7,8SJQL[NWL\4G.*=[WIR@]M;6/N#X1_MH^&?%,
M]MH7Q'L[;P7K,[I#;ZU;RR2>%[R9OE59Y)RTVB2,Y`!N&E@Y^:=.`?R7B7PK
MQ^6PJ8O(JLLTPL$Y2H226+IQ6K<5&T:Z2WY%&?:FS]PX1\:,LS6I2P/$=&&2
MXR;488B#D\%4D^DG*\\,V]O:.=/O5CL_MV.2.6-)8G22*1%DCDC8/&\;@,CH
MZDAD92"""00017Y.XN+<9)QE%M--6::T::>J:>ZZ'[=&491C*,E*,DFFG=-/
M5--:--:IK<?2&%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`>)?'7
MXT:1\%_"3:K,L-]XCU,RVGA?0GD*&_O5"F6YN=GSQ:9:)(LL\@P3NCB4AYE(
M^KX0X5Q/%&9+#0<J&!P]IXK$)?PX.]HQOHZM1IQIQZ>]-IQBSXGCKC/!\%Y2
M\5-1KYCB>:G@L,W;VM33FG.VL:-)-2J25KWC334IIK\[OA]\'_'W[1.M:C\3
M?B1X@N-%\(;IKC4_%FI&.%[NUM&9Y=/\-6UR5M[#2+9/,7[2P%K`$8*LTBN!
M^W9UQ-DW`^$H9!D."CB<R2C&E@Z2;4)S22J8J4+SJ5JCL_9K][4;5W"+BW_.
M_#_!^?\`B)C<3Q/Q)CYX'*+RG6QU9J+G"G=RI8.$VJ=*A25U[1I4:5GRJI)2
M1V5Y\<_`7PTF_P"$*_9E^'UGJVL.7LCXYU'3KK5]6U6X.4>32K98_M^J@DDK
M)*T%OD_N[9H\%O*I<(9QGD/[5X]SJ>%PL;36`IU84*-&.Z5:5_8T?-14ZG\U
M52NE[5;CG(.&9O)?#+AZGBL8VZ;S*K1G7KUI[-T()>WK7UY92<*5_AH2A9NA
M>^#?VQO'5M-J7B?Q#J_AC394>1HM?\7:?X)L0JN[,@TC2Y(WM]F3\TT"'9MR
MY&*WI9IX89-..'R_`T<?7@TD\/@ZF.J:I:^VJIJ5^T)M<U[)'/6R;QBSVG/$
MYGF.(RK"R3?+BL?2RVE9-NWU>C*$H\O>=->[:\FCG;/X._M):>[7WA3QS%K-
M_;@9@\*_%Q+S4(T;."(;K48%;."`JL6)^ZI-=M3B?@2JE1S#*'A*,MI8O)W"
MG?UA2FUYMI)=6CSZ7!_B3AVZV4Y['&5Z?V<#GL958I_W95H)WZ)-MO97*%[\
M:OBIX8E3PA\=_!4'CK2-FU]%^(>A+I^N)`WE[KC1/$D-JDJW&V,%;D?:><G>
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MDM$FDOT`T[4;#5M/L=6TF]M=1TO4K2VO].U"QGBN;*]L;R%+BTO+2YA9HY[:
M:"1)$D1BK*X8$@U\"?IA=H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`
M(Y98K>*2>>1(88(WEFED8)'%%&I>221V("(J*223@`$FJC&4Y1A"+E*32BDK
MMMNR22W;>B1,YQIPE.<E"$$Y2DW91BE=MMZ))*[?1'Y7Z/I%]^UU\?-8UC4)
M+N/X:^%&2(;&>,+X>MKB5-*TJV/(@O\`6[F.XNYV&'2$S$',<0K^AL3B:/AI
MP;A<+0C!Y[F";U2?^TSBG5K2_FIX6+C3IIZ2GRWTE,_EC!X.OXN<>XS%XB52
M'#64M1T;C;"0G)4*$/Y*N-FI5:K7O1IN=G>,$=M\4]<\1?'3QY#^SQ\(_L^C
M>`/"`BM?%6IV:F+2@FF21VTZ2K;[5DT?3I56UMK*,@7=VC$GRH5>/R>'<'@>
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MO^'_`,-](O9Y?CG^T1JWBGQBLA-]H?A&WN?$T]I-@+)9MJ%\T\-O./D7RVCL
M=NPIY?R\>WEF<Y[B*,(\(\$T<MRMK]W7QDH82,X[J:I4^2<H[OF4JM[WYM3Y
M[-^'N',)6J2XY\0J^:YPF_:8?`0GC)4I+XJ;K5'.$)+1<LHT>6W+RZ7.03PE
M^S%K%TT/AOXM>-_!%^OE&QG\8^%UGL%N=RE6EO=&$4MJN<GS7:)4X;<<8/IO
M,N/L)34L=PW@,THZ^TC@L5R5.76]J=;FC+_"E)RVMJ>.LG\,L55<,MXLS+),
M0N7V4LPP2G24[JUZF&Y90[\TG%1WOW[/6-6^)_PJTFRT[XFVVE?'#X(ZN8H;
M+4VOO^$@THQ'<J2>'/%6&O\`PWK*1(_E17#A"8RL9R"Z^5A<-P_Q!B:M?(*E
M;A'BS"IRG25/ZM6ONUB<)I1Q-"3:YY07-9IRW2?M8O%<4<*X2AAN)J5#C?@G
M%N,:=9U?K5#E=TG@\;9U\'B(I?NX3:CHU!73DNO\6Z7X#_8E\":Y^UA&WC/Q
MEHT.C:1:>%?`+)::+J,<GCJYTZWL[3Q)K?[Y!!;_`&B-7E:R;RV0,(IYQ&&_
M.>+N.\?F^73X>Q>!PU.OA<3;$8BC-SA5J8>4H<U"$E^ZC.5VY*4FX^ZK1DT?
MJ_`WAKEN09K3XHP&8XJIAL9A%+"82O3C3J4:>*A"HX8F<9?O90BTE'D@E-<T
MN:44SYU^(G[.6F?\%7O"WPQ_:<\$>)K[X-:I;:=?_#KQ-X6\5:6WBBQ%MX>\
M0:E=O>Z#J.GW6GF\ECFU:\"NT,$5R&C1Q9S6TOG?F9^O'[$_"CX>:;\)/AGX
M"^&&CWMYJ.E^`?"FB>%+'4-1\H7U[!HMA#8K>72P(L<<TWE&0I&H5=^U>`*`
MV^1Z#0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`>"?M.>*)O"'P0\=7
M]K*\%Y?:?#H%K*F0R/K]W!I<S!E93&5L[FY(<?=(!P<5]CP#E\<RXLRBA.*E
M2HU)8B:?;#PE5BK6L[SC%-=5<^#\3<TGE'!&>UZ4G3K5Z4<+!K1IXJ<:,FFF
MK-4YS::V=F>'^#8U_9^_9%OO%,*+9^*/$.C_`-N+(R^7.-9\4F&P\/H,A6/V
M'3IK*41D\&WF*YW?-];FC_UR\2J.72?M,OP-;V%D[Q]AA.:IB7U7[ZK&I&_5
M2C?;3X?)8KP_\(Z^:0BJ.:YCA_K*DU:7UG'<M+"K6S_<494Y\KV<9M;Z\?9^
M'M8^$GP'\'^!_"J%/BY^T)JEK:W>H%O],LK74[=;F_E>Y7+11:=HUS%"SY)C
MEU"[N$.X9'IU<9A>(^,,SS;,'_QC7!5*<H4[>Y.=*3C32CLW7KQE-*WO0ITZ
M;TT?D4,OQG"7`F49'E47'BWQ`K0A4JW_`'E*G7BI5&Y[QCA\/4C3D[MPG6K5
MHZJZZ&\\.0^'+2Y^`?PUUI/!7@[P;HL&O?'SXL`QV^HE;VT:X?2;:Z4YCU6\
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MB%%W]E2J:SA&JXJ2Y90A%22CI^+_`(=?&JQL+B3Q+X=^%'QX\/(6DO=#'A:#
MPAXO-JJ?O)-"O+)?*AOQ'N""-WE/W4W$@'GRS.^%:E:$<!C<WX.QCLJ=?ZW+
M&8/G;T6(A-\SIWWNE!;RLE<Z<VX=XSH8><LRR[(^.LOC=U,/]2C@,?R):O"S
MI)1A52O;EE.H]H)MV.1L;;0OV8OA[X@^-]GHWQA\1?#O7[+0T;X"VOA/^V_%
M&CZQK.N6-C]NGL;J\3<+%@1YLD43F&0&669O)QYO&/%%;,53R[%X?!ULWRJO
M*/\`;&!J^[B**BTHT^2*2C/F4IVFXJ46H0A>5_6X"X,H9.ZV:8'$X_"Y'G&'
M4O[!S&C:6%KN<6Y5'4DVY4^1PIOV<92A).<ZEHM='\.?V</BE%\=_C3\1_BA
M\7+OXE?!#XL:)-:Z#\#_`!997U_I&BP:G>:9J%K9ZOX<UEI=)L!HUC;76FQ1
MVD#&Y6_EEN1'*A5_SL_5#[-T#P_H7A71]/\`#OAC1=*\.Z!I%NMII6B:'I]I
MI6DZ;:J2RV]CI]C%%!:0AF8[(XU&6)QDF@-O*QKT`9L^LZ/9W4=C<ZKIMK>R
MD"*SGOK6"ZD+8($=O)*LCD[EQA3G</6@"P+VR^U&P6[M?MRIYK60N(OM2QD`
M^8;</Y@3#`[MN.1ZT`620`22``,DG@`#J2>PH`KVE[9WL1FL;NVNX0YC,MI/
M%<1!U`+(9(79=X#*2,Y^8>M`%:ZUG1[">.TO=5TVRNI<>3;75]:V\\F<D>7#
M+*KOD`_=!Z4`6KB[M+(1F[NK>T661883<31P"29_N11F1EWR-V5<D]A0!8H`
M0D`$DX`Y)/``'4F@"O:WEG>QF:RNK:[A5S&9;6>*>-9``60O"S*'`921G/S#
MUH`LT`9UYJ^DZ;)##J&J:=82S_ZB*\O;:UDFSN_U,<\JM)]UON@_=/I0!8N+
MRSLHA/=W5M:0%E59KB>*"(LX)11)*RJ68`X&><<4`45U_02RHNMZ069E1%74
MK,LS,0JJJB;)8L0`!R2:`+SWEG'<QV3W5M'>3(9(;1YXEN98UW;GC@+!W0;6
MRRJ1\I]#0`MVUPMI<M9HDEVMO,UK'(0(WN!&Q@1R64!#+M!.Y>#U'6@#Y8^&
M>N_&6\\=6MKXFB?_`(1\WE^D_F"1KUM/;1M3N-4N-?M2B0^'M0LO&$6AV.FV
MT*@7>G:A/-%OC@=U`/J^@#XT_;C,K_";P[9Q/M74?B3H%E,A.U)8Y-%\32I'
M)CHGVB&!^G6,'M7ZCX2<L>),=5DM</EF(J1?6+5?"Q;7FXRDOF?C7CCS_P"J
M>7482Y5B,XPE.2V33P^,DD_+GC&7R+_[4NGQK\/OA;X.MX0NEZM\3_`/ARXM
MHN,:=#%=;((SQM`%M&!T^Z*Q\/:S_MGB',YR_P!HPN59AB8R?_/URA>3_P#`
MG?U.GQ1H1AD'"^3TX<N%Q><Y9@Y0CI^Z4*B4$^GPI+;8ZS4;.+5OVIO#,,Z1
MB'P5\'=4US3$V`[;WQ!XD_L&=US_`*LI90;5(YQ*PZ&O-H5)87P]Q\H-\V:9
MU2P]5WM^[P^&^L13[WJ2N_1'JXBE'%^*66TYQBH9+P_6Q5%6U57%8MX637\M
MJ2MIW///!GAV+Q)H'@+1]4Q(GQ5^)'COXG>/5DB0?VY9>&-4NY],T6YPQ$E@
M;Q?"JM`1L:WLIDP`Q#^WFF-EE^-SC$X;W'PYEF7Y5EUF_P#9YXNE"-6O'9QJ
M<CQ;4_B52<9:V37SN39?',L!D&#Q6JXJSC,\YS1-)?6:>"K5)T<//5ITG56!
MO3^%TJ<XV5W?[2`"@*H"A0``!@`#@``=`!7Y7^9^TI)))*R6R.:\2:CJUI%;
M:;H5A=2:MK<>K6.FZP;%+[0/#FHPZ-?WVGZEXIB74;2X_LA[VV@M]EH9)9);
MF*+]TLAFB`.1\&?#.ST;7U^)7B);6]^+NN^!/"WA#QWK^BW6O6?AG5)-`1[F
M>30_"^H:M=6VCVCZM<WDL9"M<^2T4<T\GEY(!ZI0`4`?FO\`MJ?%WXIZO\5O
M@O\`L=?`OQ--X$\;?&=+[7_&OC^RC9M6\&_#G3/M_P!KGT:52IL[^[BT?7G%
MQ')#,&TR&WAFA>]\V,`ZC1_^"9/[(]GI+VOB/P5X@\>>(;F"W&I>.?%WCOQE
M=>+KV]A.]]2CO[#6K2+3+N24[C]A@MUX'!.2P!Y5^U_^SSJOP<\+?"/]I+]G
MBWU67Q[^RAIUA87VFW5]=ZGJ7CKX,:='+#K6A:Y?2%I]5DT[3+B_9II`\QL;
MW4FW-/#;[0-O*QJ_M*_M12_%SX/?"'X9?LT:E]M^)?[86GQZ?X?N;>5A=>`?
M`,L9B^(?B/73:DR:7/I<*:GI4CC8\<MKJ<T#-+IP5@#COCK<>(?V>?#G[,O[
M`?[*^L_\(9XV^*DLUGJGQ#\H-JWA_P`+V,AG\6^,F"[GCU[6K]M;OC/"V^"/
M2;N"U:!WMI+<`]MT/_@F3^RC:Z2\/C3PMXE^*'BF]LXXM:\>^.?'7C"\\4ZG
M?AC+<:K%<6.MVT.E74MPSOFSBC8#`9W.YW`/!/\`@H-X$T+X6_"7]CKP!X4;
M5(_#WAC]ISX>:;I*ZGJEYJNH)9;-=N(X;K4KR1KB]\LS%%>=W?:B;F8KN(&W
MR/U_H`^(O^"@?Q8U3X8_LZ:]HOA,R2?$7XQ:GIOP;^'MG;,%NY]<\<R-I][-
M;8^9)H-"_M1XI%^[<M:Y(W9H`^6OV/?"=U^QG^U7XL_9+U/5;W4/!_Q8^&GA
M7XG?#G5+Z4O'=^,_#>C#3?B!9VCN$!EO)['7;ORE`:.UT2QW1@2AJ`/H#]NW
MXZ?$GP+!\(_@9\#[JWTOXP?M&>+I/"&A^)9A'(?!?AZU;3XM?\1P1NK+'>H-
M5M1%.RL8H8;Z:$&XMXBH!#X:_P""9G[,-KI9/Q(T?Q3\:/&=[9R1:[X^^(?C
M7Q;=Z[J-]<LTMWJ%I#8ZY!;Z1(UP\CQF%6F0%1)<3.#(P!\\?\%(/A3X2^#7
M[#7A;X:^"O[8@\)Z1\:O"QT^#6-<U'6;ZUMM;N_%VJW-D=7U&=[N:TAFOYHX
M1/-(\<21IO/E@T`?07AK_@G_`/L)Z;?^'M7TGP'HJ:YI]YI&J:9)%\2_%ES*
MNK6<]O>6<D=N?%KQW+B[BC81^6ROC&T@XH`\D^-K,O\`P5G_`&45#NJ'X)>(
MR4#L$)`^+W)0'![=NP]!@`_6B@`H`*`/ES]L/2&U#X):KJ,48:;PKKWASQ+&
M21^Y%MJ*Z?<3!3]\K::G<#:.H8^E?H/ACB5A^*\/0E+EAC\/B<*UWYZ;JQCY
M7G2CKW/R_P`7\&\1P5BJ\8<T\KQ6$QD=O=<:JHRE;K:%>6G9LN?M#"/5O@[I
M/C2Q1KJ#PGKO@3XBQ>4K+.^EZ?J=C<7LD&/]4W]EWEQ(S-PJ*Y/2LN">;"\3
MXG*:K5*68X?,,M=_A56K2J1@I=U[6$8I+5R:MN;^(/+BN$,)G5"#KPRK$Y;F
MT5%-3=&G5IRG*'\K5&K*;;T44[G2ZX\&E?&;X;^,(C;OI7C3PEX@\`M?C.P7
MIELO&7AQ5G5MA6[AT_64BR,,V%!+2(#PX13K\+9YEC4HXC*<9A\Q5/9\EIX+
M$^[:_P"[E4H.5MEJU:+9Z&.<,)QGPYF\'!X3.<!B\J=5;>TYJ>881*2=K58T
ML0H:6;T3O**,+PS9+X7M+*U:-WN?A%XP\266I1LOFW<G@?QE)>:C9:S"J1AO
M(CL[_3;B01*5_P")#?PKN>#CKQ]5XZI5J)J-/B3!86I2:]V$<?@E"G4H.[MS
M2G3JPCS-/_:*,W93.'+*"RNE1I<K=7A#,,92K)J]1Y9F+J5J>(BDD^6-.K1J
M3Y4U_LM>FKR@?1D<B2HDL3I)%(BR1R1L'1T<!D='4D,C*0002"#D5\.TXMQD
MG&46TTU9IK1II[-=5T/T:,HRC&46I1DDTT[IIZIIK1IK5-;CZ0PH`*`"@#\C
M_P!KO7)_V?/VZ?V9_P!I[Q5#)%\(-2\'ZK\&/%_B%+.>>W\*7M]<>)KFUOM1
ME@)\B&3_`(22UNERC,UOH>I^6KN@``V\C]7])U?2=>TVRUG0M3T_6='U&!+K
M3M5TJ\M]0TZ^MI/N7%G>VDDD-S`V#AXW93C@T`6B+:]MF4B"[L[J%D92(Y[:
MX@E0HZ,#N2:%T8@@Y5@2#D&@#\<O^"<?PI\!^%?VF/VWKC1="BMI/AQ\16^'
MW@02RR7"^%?!^I^(O%^I7^B:0LQ/V6WFN=-T_<5^;;:A<_O)3(`=3^W'J-]\
M"_VLOV3?VK]:MKF3X5^'5UKX7^/M4M-/FOO^$5C\1#5H[?5+Q(%9_)FL_$&H
M31^6A<G098T#2W$2,`?JEX?\0Z#XJT;3O$7AC6-,U_0=6MH[W2]8T>]M]0TV
M^M9E#1SVMW:R/'-&0>JL<'(.""*`/S'_`."HLL4_A;]EF2WECFC;]JOX>A7A
M=9$)6WUE&"LA()#JRG!X((/(H`_5&@#\8_C]XI^+GQG_`&[?#EE\%/ACI7QB
MT3]C;2H-6UK0-7\:6'@S0A\3/'5G.]O>S:K?ADFOM*BMM):"VBBD=;K0[OS&
M"94@'GO[9'B']L1/^%4_M*^-?V:/#'PW?]FCQG8^*I_%7AOXKZ)XTU"[\-:U
MJ6E:9J_AN^T:RMH9WTF\G^QI-<#S?L\4URVU(Y9I`!MY6/5?VY]?T_1O&W[$
M'[<>CVUYXA^%'@_7K&3Q5>::OGR:=X3\>1:/JFAZXL,*L2#:2ZJI#,$-R+*V
M)#W0-`'ZS^$_%WA?QUX?TOQ7X,U_2?$WAO6;6*\TO6M$O8+_`$^\MYXUD1XK
MBW=E#;77=&VUT;*NJL"``?FI_P`%=A;WO[*.F0[DG@D^,_@2UF$4@(R(/$<%
MQ"6C;*2*P=&&0RL"#@B@#UKP-_P3<_8\\%:]X3\<>'/A=?:?XF\,:EHWB71;
MZ3Q_\0[L6>LZ7/;ZA97+6=YXHDMK@1W<,;&*:%XVV[60J2*`/"?C8#_P]I_9
M1`'3X(>)#@=@%^+Q)_*@#]::`"@`H`P/%7AVQ\6^&M>\+ZDN;#7](O\`2+KY
M=Q2*_MI+<RJN1\\9D#KR/F0<UV9=C:N68_!X_#OEK8*M3K0Z:TY*5GY2M9^3
M9P9KEU#-<MQ^5XA?N,?0JT)_W55@X<R6FL;\RVU2/"O@'=CQ%\,=6^%?C.&.
M?7?A]+J7PU\6Z=,Q8W>FQ12V^E7P##<UG?Z')%Y<HR',,C`\8'U_&-+ZAG^&
MXARJ3IX/.%2S3!U(JW)5;4JU/313I5T^:/12BFCX;@.JLPX9Q?"V<0C+'9`Z
MV3XZB[^_12E"A42>KIUL,TH3^TX2DF5?!VCRZQX5UKX#>*M1N+/QC\.OL$_A
M7Q"%'VZYT"PNQ<_#WQYIA<@7%Q92VUO8WL:MCS]/FAF(2[&_3,\3'"9CA.,,
MMH1GE>=^TCB\->U.&(J0Y<RR^K;X8U5.56A)K^'4C."<J;MCD^#EC,JQO`>:
MXB5#..'O93P.+2_>2PM*ISY3F='92G1E"%'$13_B4ITZC4:UGU>F7NI>(-1\
MX1V7AOXQ^$]/33]>T6\>=-#\4Z&\Q9;F!HP9+[PQ=W)EN+'4(DFGTRYGFMYX
MRS7-O<^=B*-#`4.2\\;PQF-1U,/7@HNO@ZZC9QDG:-/%4XVAB*,G&GBJ48U*
M<DE2J4_5PM;$X_$<_+3RWC'*:2I8K#5')8;'89RNIQ:O*I@JT^:IA<1&,ZN"
MK2G2J1<G6I5=:PU>TTAQ:1WMUX!N9))`?#GBJQ^U^'HYV=6EDT/48+J&W-F2
M)F6.SU)8E\Q&:VA),;<U;#5,0O:.E#-Z<4K8G"5/9XEQL[*O2E"4U/X4Y5:#
MF[-*K47O+KH8NC@W[*-:>05&W_L>.I<^$C)M.3PU6,X4_9OWG&-'$J"NFZ--
MMQ=S4/$UA(3!/X]TQH96,<=CX-L'O-=N#M8/;1M:WNJSB0DI@VUK#*`&PX/S
M)E0R^M%*5/)JL9P5W/&U%3P\.TFIPP\+;W]I4E!Z73V>V(S.A+W*F?4>23LJ
M>74G4Q4]'>"<*F*G=MJWLJ4)K6TEO'HM%U>:*PGN]3TW_A%O#UE':P:;)KVH
MHNJ21?+$;C4XY9'33T>1X8XDGNY;AVR9EC=PE<6*PT76A2P]?Z_C:CG*HL/2
M?LHO5\M)Q474:2E*;A3C32LH.23D>C@L7.%"=7$X;^R\OH*$:+Q59*O*.D>>
MLI.4:2DW&,(SJRK2=W44)-1.OKS#UPH`YKQ?X.\*>/\`PYJGA#QKX>TCQ3X8
MUJW-KJFA:Y8P:AIMY"6#J)K:X1E\Q)%22.1</'(B21LKHK``^%9O^"7_`.RN
MEQ.-&L_B9X5T2[<O=^$O#GQ2\6V/AFYW,9&2:SGO;BX\LR%GVI=*`6.W`XH`
M^Z/!?@_P_P##WPCX;\#>%+.33O#7A'1=.\/Z#8RWEYJ$EGI6E6T=I8VSWVHS
MSW-TT=O$B^9/-([8RS$T!MY6/-?A7^SY\/O@[XP^+?CCP<-<&N?&KQ/'XM\:
M?VKJOV^S_M:.XU:Y7^R;;[/'_9]MYNM7O[O=+\OEKNQ&*`/4_$_A?PYXTT#5
M?"GB[0]*\2>&M<M)+#5]"UNQM]1TO4;27!:"[L[E'CE7<JNI*Y5T5U(900`?
M"-Y_P3"_97-Y=2Z#8?$CP5I=ZSM>^&?"/Q.\5Z9X<NO,;>ZR6-S>74J1&3YO
M+CGC0$#:H``H`]8^)'[%7P.^)OPD^'OP2U>S\4:/X"^%^I6NJ^$+7P]XGO;7
M5+*[L[/4;*%[G6=16]NKWY-4NY"TKE_,97#C:!0'X'GW@3_@G7\#_AYXT\+>
M.M$\5_&RZUCPCKNG>(=,MM:^)^HZCI,]]IEREU;QZC8-9(+VS:1`)(&8+(A9
M&^5B"`?1'P;^`'@'X&3?$.]\&_V[=ZM\4O&M_P"/?&>M^)=5.L:MJFN7^XNO
MVLP0^78122W4D4&T[&O9SN._"@;>1Z#X[\%>'_B/X+\5>`/%=H;WPWXQT'5/
M#FMVJL(Y)-.U>TEL[DV\I5O(ND24R13!28Y421?F04`<5\.?@;X"^&GPBTSX
M'V-K>>)_AYI6FW^C0Z3XYFMO$IN=&U&\NKR32;\W%G'%>:?&UW)%%#)"0D21
MQC(C7`!\LZC_`,$Q_P!E>74;Z^\.Z7\0O`%MJ<DDFHZ'X$^)/BC0]!O!*2TL
M3Z=+=W(AMF)'[B!X8U"@(J@8H`]2\5_L4?`GQ9\!]!_9QGTSQ+I/PQ\-Z^OB
M;3+/2O%&I/K*ZO\`:]8U">XN=<UEK^YN5GOM=U*=TD8J&E41B-(T50#R#3/^
M"8_P`TC4=.U*V\7_`!X:;2[VSO[:*?XKZD]N9K*>.YA26(6"[H=\2@J"N1D`
MCK0!ZI\?_P!B+X,_M(>.M"^(OCZ[\>Z?XI\.>&XO"NE7G@_Q9)X<6#2HM1U;
M4Q\L5E*XNFN-:OE:5)$W1LB$87D`@^"G[#WPD^`WCJW^(/@[Q%\5]2UNVTS4
M=*CMO%WC^]\0Z.;;5(XX[AGTV:TB1YU6-2CEOE/.,@8`V^1]CT`%`!0!\X_$
M_0=;\!^+K;XY>"=-GU1K;3X]'^*/A:Q4M=^)?"5NV^WUK38%7]]X@T3+2HO#
M36RM"&`7#_<9!C,)F^6U.$<UKQPRG4=;*<54TAA<9)6E0JR^SAL7\+>T*K4[
M-NZ_.^)L#C<BS:GQMDN&EB73I+#YU@J?QXO`QUCB*,=I8K!_$MG4HKDYDHM2
M[#6]#T3XKZ%X;\=>!O$,6F^(+"`ZIX'\;:<JW`MUNU7[7I.K6FY?[1T.\V"W
MO],G*D-'E?*N8$=/,PF+Q?#>+QV3YM@G5P567LL=@:CY.;D;Y*U&=G[*O3OS
MX?$0NFG9\]*;3]?&X'!<4X'+L[R3,(X;'T(NMEN8TDI<G.E[2A7IW7M<-5M[
M/$X:=FFKKDJP37-S>(_#WB.YTWPS\6M*_P"%?>/]/F<Z!JT6HS6%E>W;1*LF
MI?#[QM&(1*DZ[3)I5P\5S@"*ZM)HTW/WPP.-R^G7QW#>(_MC)JT5]8HNG&<Z
M<+W5+,<`^;E<->7$04J5_?I5H2=EYD\QR_,:N&RWBW"?ZOY_AY/ZK7C6E2IU
M*C5G6RG,ER74U;FPM1QK6_=UZ%2*N^\73?B3I:&WM=:\->+K+81'_P`))87.
MB:L1E`J76H:&D]E=CRPQ+II5L2S<C%>.Z^15VISPF*RRK?7ZK4C7HK>[A2KN
M%6&O1XFI9'NK#<282+ITL;@\VH6]WZY2GAJ_2RG5PRJ4:FEWS+"4[MZJQ%&O
MQ/Q)%8Z-\.O#RMMQ.=1US6R&#+O=["VT?2%DX,Q4?:T.2N2<FJ?^KZY95<5F
M6,:O[OLJ&'[V2J2K8EKI?]V^OD3%<3^]&A@LHRY.WO>VQ.)ZJ[=*&'P:?VK+
MVJW6NYSNMV/A3PF]GXE^+7C4:]?6TZRZ)9:I'!9:1!?QG]R?#/@G3A*^I:P&
M<"*60:I>JS#R9$R!7;A*N8Y@JF`X;RGZE1G&U>=)RG6=-_%]:QU7E5*BU\<8
M_5Z#5^>,MSSL=0RG*'1S+BS._KU>E)2PU.NHTL/"JOA>#RVCS.MB+OW)26*Q
M"DU[.<=$=OX.\0>(O$HO]3U+PO/X5T-VA7P[!J\QC\37\(\W[1?ZOI"1F/0X
M9#Y/D6LD\MSMWM<)`Q$8\G,\%@L!['#X?,(X_%Q4OK,J,?\`9:<G;EIT:S=Z
M[C[WM*BA&E>RIRJ).1[>3YAF.9*OB<3E<LJP+<5A(8B5L;5C[W/5Q&'2Y<+&
M7N^RI2G*M:[JQI-J!VU>4>V%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`
M!0`4`%`!0!\^:K\./%/@#6]1\8_!<V'V?5KAK[Q5\+-5N&L?#>O7;L6N-6\-
MWJAE\*^(I1][$9L[@A3,B%=Q^TPV>9?G&$H97Q2JD9X6/L\)FU&*GB</!?#1
MQ5/1XO#1Z:^WIJ_))IV/S_%<.9ID&-Q.<<&.E[/%2=3&Y)7FZ6$Q-1N\J^#J
M:K!8N2T?N_5ZKM[2,;7>MIGQ2^''CL2>#/&%BGAOQ!.JQ7WP_P#B-I]OI][,
MYP`;!-0#6.OV[.6\JXT^:X#8#80D"N>OP]GF3<N9Y75>-P4+NGF&65)5(177
MVCIVJX>27QPK1A;;4ZL-Q1PYGG-DV;T%EN83LJF59O2A1J2;T7LE5O1Q4&[^
MSG0G4NK2M&Z-B'X2:%INW_A%=?\`&G@^W59##I^@>*+V31HGDV_O(-%UL:A8
MPJJJBI%%`D2JH"(!7++B3%UK_P!H8+`YE/2]3$82"KM+I*O0]A6;;;;E*;FV
M[N3.R'"6!PMO[*S#,<FII/EI87&U'AXN5M8X;$_6*$4DDHQC3C"*TC%(67X9
MW]VAAU#XH_$ZXAX(2VUC1=#D#`YS]KT#P]97.#TV^=CVI1SZC1:E0X?RJG)=
M94:]=?\`@&(Q-6G\^6X2X9KU$X5^*,ZJ0Z*&(PV&=_\`'A,)0J?+GMY%7_A'
M_@]\)!+XGU(Z!H%Z5/F^)_%6K/?Z[/D8:.+6?$%Y<7S[MYQ;V\H7Y\+&`<5I
M]<XFXBY<OPZQ&+I1^'"82BJ6'CUNZ&&A3HJUOCG&^EW*^IDLNX/X1YLRQ'U7
M`5VM<;CJ[JXJ5]XQQ&+J5*[O?2G3E;6T86T.7E^(7CCXF'^SOA#I%QH'AV?Y
M+KXK^+M,GM+);<L0TO@OPQ>K%=^(;ED!\N[NTM;-&()\W@'T(Y)E/#_[[B3$
MQQ>-AK#*,'5C.?-VQV*IN5/#13^*G2=2M);<FYYDN(,[XE_V?A'"2P.73TGG
MF/HRITU%_:R[!5%&KBYM?!5JJE0B]^<]QT/3)-%T?3-)EU/4=9ET^R@M9-6U
M>=;C4]1DBC"O>7TZ1HLES*P+L515RV```!7R6+KK%8JOB(T*6$C6G*:HT8N%
M*DI.ZA3BVVHQ6BNV^[;/N,#AI8+!X;"2Q-;&2P].,'7KR4ZU5I6=2I)**<Y/
M5V2796-6N<Z@H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`,#
MQ%X5\,^+;$Z9XHT#2-?L,[EM=7T^VOHHWX/F1+<1MY,G`^="K<=:[,#F./RN
MK[?+L96P-;;GHU)TW;L^5JZ\G='GYCE669M0^K9IE^'Q^'O=4\12A5BGWBII
M\K\XV?F>:Q_`CPCIT;P^&-:^(/@R!@H6U\,>/_$]I90E%VHT.GWM_=VL84`8
M00[/E`V;<@^\^+\RJR4L=A,NS.:O[V*R["SF[N[YJE.G3J._5\W-K>]]3YN/
M`F48:,H99C<VR:F[6IX+-<;3I1LK)QI5*M6DK:>[R<NEN6V@B_!:-F'VWXI?
M&>_@V.CVDOCR6QAD$@VMYCZ-IUE.?ER`!,!\QXSC!_K5**_<\/9)0G=-3CEZ
MG*-M=%6J58?^2W$N"HMVK<4\15Z=FG"6:2I1=][O#T:%3_R=+4T-`^!GPL\.
M7L6J6OA*SU+68=A36_$MQ?>*=85T#*LD=_XAN;R2"3#L,PF/KTX&,<9Q;Q#C
M:4L-/,IX?"RO?#X6-/"4;.SLZ>&C2C):?:YCIP'`W"V6UXXNEE-/$XV-K8G&
M2J8VNFKI-5,7.M*#U?P<J\CUJOFSZP*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`
- -"@`H`*`"@`H`*`/_V3\_
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>c95090p9509002.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 c95090p9509002.jpg
M_]C_X``02D9)1@`!``$`8`!@``#__@`?3$5!1"!496-H;F]L;V=I97,@26YC
M+B!6,2XP,0#_VP"$``("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("
M`@("`@,#`@(#`@("`P0#`P,#!`0$`@,$!`0$!`,$!`,!`@("`@("`@("`@,"
M`@(#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#
M`P,#`P,#`__$`:(```$%`0$!`0$!```````````!`@,$!08'"`D*"P$``P$!
M`0$!`0$!`0````````$"`P0%!@<("0H+$``"`0,#`@0#!04$!````7T!`@,`
M!!$%$B$Q008346$'(G$4,H&1H0@C0K'!%5+1\"0S8G*""0H6%Q@9&B4F)R@I
M*C0U-C<X.3I#1$5&1TA)2E-455976%E:8V1E9F=H:6IS='5V=WAY>H.$A8:'
MB(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4U=;7
MV-G:X>+CY.7FY^CIZO'R\_3U]O?X^?H1``(!`@0$`P0'!00$``$"=P`!`@,1
M!`4A,08205$'87$3(C*!"!1"D:&QP0DC,U+P%6)RT0H6)#3A)?$7&!D:)B<H
M*2HU-C<X.3I#1$5&1TA)2E-455976%E:8V1E9F=H:6IS='5V=WAY>H*#A(6&
MAXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&Q\C)RM+3U-76
MU]C9VN+CY.7FY^CIZO+S]/7V]_CY^O_``!$(`"L"10,!$0`"$0$#$0'_V@`,
M`P$``A$#$0`_`/W\H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`
M*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@
M`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*
M`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`^?M3^+?B+3Y_
M&6HQZ'HTOASP3XAM]$U%'O;N+6;J.XN!`+NS/E&VW`L"8F&>>&.":`V\K'OD
M$R7$$,\>?+GBCF3<-K;)$#KN7^$[6&1VH`EH`\=\2>/?$UEXNU?PQX?TK1)E
MT+PQ_P`)/=3ZM=WL+74"DB2TMA:QE8)<8VO)N7KG%`'>^#_$<7BWPSH_B.&V
MDLDU2T$_V61@S02+(\,J!P`)$$L;[7`&Y=K8&:`.EH`\O^(7C76?"NH^$-)T
M2PTJ[NO%%_>6"R:M<W%K;6SP);-&[26RL0A,[;CM.-HP.:`/0-)DU&73;.35
MDLHM1:%6NTTV66>Q65LDBUFF17DBQ@AF4'F@#0H`\N\:^.=3T/Q#X=\)Z%9Z
M3)J^OPWEU'=Z_>36.E0PV@/[@26Z,\MY,X941>^W@EQ0!Z19M=-:6S7T<,-Z
MT$1NXK9WDMX[DHIF2"1U5GB$FX*S*I(`)`H`LT`>6^,_'.J:+XE\/^$-!L](
MDU;7;6[OENM?O9K'3(H;8LBVT;6\;/->S.K!4'3Y>#NX`/2K4W+6MNUY'%#=
MM!$;J*W=I((K@HIF2&1U5I(EDW!6*J2`"0,XH#;RL6*`"@`H`*`/GJX^+WB*
MTC\1:XVA:._AKPSXN/A>]A2]O%UR4?:DMQ?6VZ'[,_\`K$/DX#$D@'`S0!]!
MHP=$=<X=589&#A@",CL<'I0`Z@#Q_5?'/BH?$"[\$Z!IOAUTLM)LM6DO-9O[
MRT=HKB2*.6*%;>)P\P:9=JXY`))&*`/8*`"@#SW2?&-W?_$/Q1X,>RMHK/0-
M+TR_@O4DE-S/)?1VTCQRQGY$13.0"O)VC/6@#T*@`H`\?T?QSXJUOQOXB\.V
M.F^'8=(\,ZQ;6%[<W=]>Q:G/:W`E?S;*V2)HY9U6&3*DJN2O/-`'L%`!0!Y#
MJ7Q/?3_B38>"UT^%M(F>TTZ]UDR2![77-1M+F]L;%5`\O#Q11`[CG,A].0#U
MZ@`H`\GU[QWKD?C>/P/X:L-#>^ATJ/5[J?Q!J%Q8QW,<TH1+/2X[:)VGN=AW
ML3D`!OE^0F@#U==VU=P`;`W`'(#8Y`)[9H`6@#R'Q-XY\36/CNU\%>'M.\/S
M//H*ZT;O6[V\LXUQ<W$$D*FVC?)Q$A4;<G+9X%`'K<>_RT\T*)-B^8$)*!]H
MWA"0"5W9P3SB@!]`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0
M`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0!X+X9^%]O=^*/'6J^+]%>6VNO
M%K:IH,<]^[6%W;YE=+J;3[6Z\J9ED*E1=1EAG&,9%`'O(````P!P`.``.@`H
M`6@#YL\?_#CQ/XF\9^*-2TY+BSMIO!MG;Z5>1WL<%OJ&J6ETDTFC7L"3J\MI
M<0"2-A,GE9923Q0![GX5:[/AW1Q?:.GA^\CL88;G1X?LX@L9H5$3Q6PM7:(6
MQ*[HPK'",H/(-`;>5CH*`/#OC!X6U7Q!J/@6ZLO#;^)].T;4M0N-9TQ+JSM?
M/M9H[()"6O+B)3YAB<<$XV\XS0!ZOX=00Z'I<2Z.WA]8;.*)-%>6"9M-2,;$
MM3+;2/$^Q%7E'88/6@-O*QM4`>,?&#1;_P`1:9'HUCX$/B:>:WG.G:VNIV.G
MMX>U)V5(IB)Y$F,6W]XVP[&V*K`G!4`]%\(Z=J6C^&-"TO6+O[;J=AIEK;7M
MSO:3S)XXP'Q*_P`T@7A-YY;9D]:`V^1T5`'BOQBT+4/$FGQ:/8>!/^$CN9+:
M1M-U]=4L=.;P_J+RJJNPFD29HMBK(VPE&VA6&1D`'I?A;3]1TGPWH>FZM=F]
MU*QTRTMKVZ+M)YMQ%"JR-YC_`#2`$;=[<MMR>30&WR-^@`H`*`"@#Y/B^'/C
M&PU*_P#$L6BR:@]K\2]0U?\`X1FZO;-]/UK0;QOW6IQ6TMU]FCU*V9G>)I0L
M@W]/W8!`/JY3N56VLNY0=K8#+D9VL`2-PZ'!-`#J`/G;Q+X3U23XJW7B6X\!
MR^+=$?2-*MK%X[_3;7['J5M-#(;T1W=W$Y,*HX^[SOR,T`?1-`!0!X=%IWBK
M1/BYXE\0V_A6\U31-?L=#TR*_MK_`$RW2U$$5DEU=2P7-RLKQ1-')E53<=AV
M@Y&0/P/<:`"@#YVT3PGJFE_%#Q-KNI>!)=5MM4\0VUSH?B-;_3471;<1SQW5
MX;9[L3,KB6,[5C+_`+HC'-`'T30`A.`3@G`)P,9..PR1S0!\JW_PW^(.H^'M
M<UWSDM_$%[XP_P"$OMO#+6U@US]JLKK[/IH&MB\VP[-.R1$#LQ\I.6-`'U%9
M23RV=K+<P-:W,EM!)<6S%6:WG>-6EA+(Q5BDA9<J2#MR"10!9H`\`^+_`(9U
MOQ9<6VG:+X(,^IP&QDTKQTNKV5B-)Q<B6\BEB$BW3(B*=HPPW2EXQN7Y@#W6
MRBFM[.T@N9C<W$%K;Q3W!X,\T<2)+,0>A=U9O^!4`6J`/GCQ[X1U.^^)5AXA
MD\#R>,?#\'AJ*P:V2^TZUV:BM[=S))MO;N(DQI(IR!@^9QDB@/P/H2(LT<;-
M&8F9$+1$@F-BH)C)4D$J>,@XXXH`?0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4
M`%`!0`4`%`&8=:T8<?VMI@(.,&_M1@CJ,>;UH`3^V]&_Z"^F?^!]I_\`':`#
M^V]&_P"@OIG_`('VG_QV@`_MO1O^@OIG_@?:?_':`#^V]&_Z"^F?^!]I_P#'
M:`#^V]&_Z"^F?^!]I_\`':`#^V]&_P"@OIG_`('VG_QV@`_MO1O^@OIG_@?:
M?_':`#^V]&_Z"^F?^!]I_P#':`#^V]&_Z"^F?^!]I_\`':`#^V]&_P"@OIG_
M`('VG_QV@`_MO1O^@OIG_@?:?_':`#^V]&_Z"^F?^!]I_P#':`#^V]&_Z"^F
M?^!]I_\`':`#^V]&_P"@OIG_`('VG_QV@`_MO1O^@OIG_@?:?_':`#^V]&_Z
M"^F?^!]I_P#':`#^V]&_Z"^F?^!]I_\`':`#^V]&_P"@OIG_`('VG_QV@`_M
MO1O^@OIG_@?:?_':`#^V]&_Z"^F?^!]I_P#':`#^V]&_Z"^F?^!]I_\`':`#
M^V]&_P"@OIG_`('VG_QV@`_MO1O^@OIG_@?:?_':`#^V]&_Z"^F?^!]I_P#'
M:`#^V]&_Z"^F?^!]I_\`':`#^V]&_P"@OIG_`('VG_QV@`_MO1O^@OIG_@?:
M?_':`#^V]&_Z"^F?^!]I_P#':`#^V]&_Z"^F?^!]I_\`':`#^V]&_P"@OIG_
M`('VG_QV@`_MO1O^@OIG_@?:?_':`#^V]&_Z"^F?^!]I_P#':`#^V]&_Z"^F
M?^!]I_\`':`#^V]&_P"@OIG_`('VG_QV@`_MO1O^@OIG_@?:?_':`#^V]&_Z
M"^F?^!]I_P#':`#^V]&_Z"^F?^!]I_\`':`#^V]&_P"@OIG_`('VG_QV@`_M
MO1O^@OIG_@?:?_':`#^V]&_Z"^F?^!]I_P#':`#^V]&_Z"^F?^!]I_\`':`#
M^V]&_P"@OIG_`('VG_QV@`_MO1O^@OIG_@?:?_':`#^V]&_Z"^F?^!]I_P#'
M:`#^V]&_Z"^F?^!]I_\`':`#^V]&_P"@OIG_`('VG_QV@`_MO1O^@OIG_@?:
M?_':`#^V]&_Z"^F?^!]I_P#':`#^V]&_Z"^F?^!]I_\`':`#^V]&_P"@OIG_
M`('VG_QV@`_MO1O^@OIG_@?:?_':`#^V]&_Z"^F?^!]I_P#':`#^V]&_Z"^F
M?^!]I_\`':`#^V]&_P"@OIG_`('VG_QV@`_MO1O^@OIG_@?:?_':`#^V]&_Z
M"^F?^!]I_P#':`#^V]&_Z"^F?^!]I_\`':`#^V]&_P"@OIG_`('VG_QV@`_M
MO1O^@OIG_@?:?_':`#^V]&_Z"^F?^!]I_P#':`#^V]&_Z"^F?^!]I_\`':`#
M^V]&_P"@OIG_`('VG_QV@`_MO1O^@OIG_@?:?_':`#^V]&_Z"^F?^!]I_P#'
M:`#^V]&_Z"^F?^!]I_\`':`#^V]&_P"@OIG_`('VG_QV@`_MO1O^@OIG_@?:
M?_':`#^V]&_Z"^F?^!]I_P#':`#^V]&_Z"^F?^!]I_\`':`#^V]%_P"@OI?_
M`('VG_QV@#21T=%>-E='571T8,C(P!5E93AE((((X(-`#J`.</@[PEDD^&/#
M^<DDG1]/SDG))/V?J30`G_"&^$?^A7\/?^";3O\`Y'H`/^$-\(_]"OX>_P#!
M-IW_`,CT`'_"&^$?^A7\/?\`@FT[_P"1Z`#_`(0WPC_T*_A[_P`$VG?_`"/0
M`?\`"&^$?^A7\/?^";3O_D>@`_X0WPC_`-"OX>_\$VG?_(]`!_PAOA'_`*%?
MP]_X)M._^1Z`#_A#?"/_`$*_A[_P3:=_\CT`'_"&^$?^A7\/?^";3O\`Y'H`
M/^$-\(_]"OX>_P#!-IW_`,CT`'_"&^$?^A7\/?\`@FT[_P"1Z`#_`(0WPC_T
M*_A[_P`$VG?_`"/0`?\`"&^$?^A7\/?^";3O_D>@`_X0WPC_`-"OX>_\$VG?
M_(]`!_PAOA'_`*%?P]_X)M._^1Z`#_A#?"/_`$*_A[_P3:=_\CT`'_"&^$?^
MA7\/?^";3O\`Y'H`/^$-\(_]"OX>_P#!-IW_`,CT`'_"&^$?^A7\/?\`@FT[
M_P"1Z`#_`(0WPC_T*_A[_P`$VG?_`"/0`?\`"&^$?^A7\/?^";3O_D>@`_X0
MWPC_`-"OX>_\$VG?_(]`!_PAOA'_`*%?P]_X)M._^1Z`#_A#?"/_`$*_A[_P
M3:=_\CT`'_"&^$?^A7\/?^";3O\`Y'H`/^$-\(_]"OX>_P#!-IW_`,CT`'_"
M&^$?^A7\/?\`@FT[_P"1Z`#_`(0WPC_T*_A[_P`$VG?_`"/0`?\`"&^$?^A7
M\/?^";3O_D>@`_X0WPC_`-"OX>_\$VG?_(]`!_PAOA'_`*%?P]_X)M._^1Z`
M#_A#?"/_`$*_A[_P3:=_\CT`'_"&^$?^A7\/?^";3O\`Y'H`/^$-\(_]"OX>
M_P#!-IW_`,CT`'_"&^$?^A7\/?\`@FT[_P"1Z`#_`(0WPC_T*_A[_P`$VG?_
M`"/0`?\`"&^$?^A7\/?^";3O_D>@`_X0WPC_`-"OX>_\$VG?_(]`!_PAOA'_
M`*%?P]_X)M._^1Z`#_A#?"/_`$*_A[_P3:=_\CT`'_"&^$?^A7\/?^";3O\`
MY'H`/^$-\(_]"OX>_P#!-IW_`,CT`'_"&^$?^A7\/?\`@FT[_P"1Z`#_`(0W
MPC_T*_A[_P`$VG?_`"/0`?\`"&^$?^A7\/?^";3O_D>@`_X0WPC_`-"OX>_\
M$VG?_(]`!_PAOA'_`*%?P]_X)M._^1Z`#_A#?"/_`$*_A[_P3:=_\CT`'_"&
M^$?^A7\/?^";3O\`Y'H`/^$-\(_]"OX>_P#!-IW_`,CT`'_"&^$?^A7\/?\`
M@FT[_P"1Z`#_`(0WPC_T*_A[_P`$VG?_`"/0`?\`"&^$?^A7\/?^";3O_D>@
M`_X0WPC_`-"OX>_\$VG?_(]`!_PAOA'_`*%?P]_X)M._^1Z`#_A#?"/_`$*_
MA[_P3:=_\CT`'_"&^$?^A7\/?^";3O\`Y'H`/^$-\(_]"OX>_P#!-IW_`,CT
M`'_"&^$?^A7\/?\`@FT[_P"1Z`#_`(0WPC_T*_A[_P`$VG?_`"/0`?\`"&^$
M?^A7\/?^";3O_D>@`_X0WPC_`-"OX>_\$VG?_(]`!_PAOA'_`*%?P]_X)M._
M^1Z`#_A#?"/_`$*_A[_P3:=_\CT`'_"&^$?^A7\/?^";3O\`Y'H`/^$-\(_]
M"OX>_P#!-IW_`,CT`'_"&^$?^A7\/?\`@FT[_P"1Z`#_`(0WPC_T*_A[_P`$
MVG?_`"/0`?\`"&^$?^A7\/?^";3O_D>@`_X0WPC_`-"OX>_\$VG?_(]`'011
M1011P01I###&D4,42+''%%&H2..-%`"(J``*````!0!)0`4`%`!0`4`%`!0`
M4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`
M!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4
<`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0!__V3\_
`
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
-----END PRIVACY-ENHANCED MESSAGE-----
